Lokelma

RSS

sodium zirconium cyclosilicate

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Lokelma. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Lokelma.

For practical information about using Lokelma, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 24/01/2022

Authorisation details

Product details
Name
Lokelma
Agency product number
EMEA/H/C/004029
Active substance
sodium zirconium cyclosilicate
International non-proprietary name (INN) or common name
sodium zirconium cyclosilicate
Therapeutic area (MeSH)
Hyperkalemia
Anatomical therapeutic chemical (ATC) code
V03AE10
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
AstraZeneca AB
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
22/03/2018
Contact address

151 85 Sodertalje
Sweden

Product information

21/01/2021 Lokelma - EMEA/H/C/004029 - II/0021/G

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

All other therapeutic products

Therapeutic indication

Lokelma is indicated for the treatment of hyperkalaemia in adult patients.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating
2 ratings